Skip to main content
Premium Trial:

Request an Annual Quote

Waters Sales and Earnings Rise, Despite Downturn in Mass Spec Sales for Proteomics

NEW YORK, Jan. 29 (GenomeWeb News) - Waters reported increased revenues and earnings for the fourth quarter of 2003 today, despite slow mass spec sales for proteomics.


The company's fourth quarter revenues increased to $275.1 million, from $256.4 million a year ago.


R&D expenses for the quarter climbed to $16.8 million, from $13.4 million during the same period last year.


Waters' net income surged to $58.4 million, or $.48 per share, for the quarter, compared with $40.3 million, or $.31 per share, the year before. This was despite a sharp 30 percent downturn in mass spec sales for the quarter, year over year, especially regarding proteomics-focused Q-TOF instruments.


As of Dec. 31, 2003, Waters had cash and cash equivalents of $356.8 million.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.